Arvinas Inc

-2.02 (-5.57%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)2.33B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$33.94 Million
Adjusted EPS-$1.43
See more estimates
10-Day MA$37.40
50-Day MA$44.41
200-Day MA$30.74
See more pivots

Arvinas Inc Stock, NASDAQ:ARVN

5 Science Park, 395 Winchester Avenue, New Haven, Connecticut 06511
United States of America
Phone: +1.203.535.1456
Number of Employees: 445


Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.